Older Adults

This report summarises what Blossom’s database shows about psychedelic and rapid-acting treatments in older adults, and the most honest summary is that it shows how little has been studied. Older adults carry a heavy burden of late-life depression and related distress, and are an obvious group to benefit from new treatments, yet they have been almost completely excluded from the trials. The result is a field rich in extrapolation and thin in direct evidence, in the one population where the safety stakes are highest.

A note before the evidence

This page is a research summary, not medical advice, and nothing here is a treatment recommendation. No psychedelic is approved for any condition specifically in older adults, and the relevant safety questions, around interactions with other medications, cardiovascular strain, falls and cognition, are especially serious in later life. Effective, established treatments for late-life depression exist, including antidepressants, psychotherapy and, for severe cases, electroconvulsive therapy, and they should come first. Decisions belong with a clinician who knows the person’s full medical picture, and self-experimentation is particularly inadvisable for older adults. If you or an older person you care about is struggling, please seek help.

A word on scope and numbers. Blossom tracks dozens of papers and trials under this topic, and those counts appear on the page. But many are about ageing biology, or are general-population studies that merely mention age, rather than trials conducted in older adults. The genuinely older-adult-specific clinical evidence is small, and concentrated in ketamine for late-life depression. Read the counts as interest in the question, not as an answer to it.

The gap, in numbers

The single most important fact about psychedelics and older adults is how absent older adults are from the research. A 2024 systematic review searched the psychedelic-assisted therapy trial literature and found that, of roughly 1,400 participants across 36 studies, just 19, fewer than 1.4%, were aged 65 or older[1]J Psychopharmacol, older adults in psychedelic therapy trials systematic review (2024). For comparison, people over 65 make up around 17% of the population in countries running these trials. The mismatch is stark, and it is the lens through which every other claim on this page has to be read.

This exclusion is largely by design. Trials set upper age limits, and they screen out uncontrolled high blood pressure, heart disease, significant polypharmacy and cognitive impairment, all of which become more common with age. From a trial-purity standpoint that is understandable: it reduces confounding and protects vulnerable participants. But it produces a circular problem. Older adults are excluded because they are complex and higher-risk, and then, because they were excluded, there is no evidence about how to treat them safely, so they continue to be excluded. The cost of that caution is a near-total absence of data in the group with arguably the greatest need.

Why the stakes are higher in later life

The reason this gap matters so much is that older adults are not simply younger adults with more birthdays. They are more likely to be taking several medications at once, including antidepressants whose serotonergic action can interact dangerously with classic psychedelics, raising the risk of serotonin toxicity. They are more likely to have cardiovascular disease, which makes the transient rises in blood pressure and heart rate that psychedelics and MDMA produce more consequential. They are more vulnerable to falls during a dosing session, to confusion or dissociation, and to slower drug clearance. None of this means psychedelics cannot be used safely in older people; it means the margin for error is smaller and the need for proper, monitored study is greater, which is precisely what the missing trials would provide.

Ketamine: the one real older-adult evidence base

The exception to the general emptiness is ketamine, studied specifically for late-life treatment-resistant depression. Several small studies, including a Bayesian dose-finding randomised trial[2]Neuropsychopharmacology, IV ketamine late-life TRD dose-finding RCT (2021) and a pilot focused on tolerability, safety and cognition[3]Am J Geriatr Psychiatry, IV ketamine late-life TRD pilot (2022), suggest intravenous ketamine can reduce depression in older adults and is reasonably well tolerated, with careful attention to its cognitive effects. This is a genuine, if modest, body of older-adult evidence of the kind the rest of the field lacks.

It also delivers the field’s most useful cautionary result. TRANSFORM-3, the dedicated trial of esketamine nasal spray plus an antidepressant in people aged 65 and over, did not meet its primary efficacy endpoint[4]Am J Geriatr Psychiatry, esketamine elderly TRD (TRANSFORM-3, 2020), even though esketamine is approved on the basis of trials in younger adults. Subgroup analyses suggested the 65-74 group and those with earlier-onset depression may have done better, but the headline is that a treatment which works in younger patients underperformed when finally tested properly in older ones. That is exactly why extrapolation is dangerous, and exactly why the missing psilocybin and MDMA trials in this group need to be run rather than assumed.

Psilocybin, MDMA and the signals we do have

For the classic psychedelics and MDMA, the older-adult evidence is mostly indirect and reassuring only at the level of "no obvious harm so far". The same systematic review that documented the under-representation also pooled the available safety data and found no serious adverse events among the older participants, only transient mild-to-moderate effects[1]J Psychopharmacol, older adults in psychedelic therapy trials systematic review (2024), and a 2024 prospective cohort of older adults using psychedelics in naturalistic settings reported broadly positive mental-health associations[5]Am J Geriatr Psychiatry, psychedelics in older adults prospective cohort (2024). These are worth knowing, but they are small, uncontrolled and prone to the bias that the people who use psychedelics and report back are not a random sample.

There is also a more speculative, basic-science thread around ageing itself, including a 2025 report that psilocybin extended cellular lifespan and improved survival in aged mice[6]npj Aging, psilocybin and cellular lifespan in aged mice (2025, preclinical). It is a genuinely interesting finding about biology, but it is preclinical and says nothing yet about treating older people; presenting it as a longevity therapy would be exactly the kind of overreach this page exists to avoid. The honest state of play for psilocybin and MDMA in older adults is: plausible, minimally tested, and finally beginning to be studied directly.

Reading this honestly

So where do older adults sit? Almost uniquely in this field, the main finding is an absence. The need is large, the rationale is reasonable, and the little direct evidence that exists, mostly for ketamine in late-life depression, is real but modest, and in one key trial fell short. Everything else is extrapolated from younger, healthier people into the group least like them and most exposed to the risks. The encouraging news is that dedicated older-adult trials are at last under way. For older people and their families, the truthful message is neither the marketing line that psychedelics are a proven gift for seniors nor a flat dismissal, but something more useful: this is under-studied territory where the established treatments still come first, where the specific risks of later life deserve real respect, and where the most important development is simply that the right trials are finally being done.